Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile.
Crawford
E David
ED
University of Colorado Health Sciences Center, Aurora, Colorado 80010, USA. david.crawford@uchsc.edu
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D018570:Risk Assessment; D012307:Risk Factors; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy / Q000209:etiology; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists